Skip to main content
. Author manuscript; available in PMC: 2021 Apr 5.
Published in final edited form as: Clin Cancer Res. 2019 Apr 19;25(14):4264–4270. doi: 10.1158/1078-0432.CCR-19-0361

Table 4.

Venetoclax Dosing and Discontinuation

Rate, % (proportion)
Achieved 400 mg daily 81% (137/169)
Maintained 400 mg daily 65% (108/166)
Required Dose Reduction 29% (51/177)
Required Dose Interruption
 Duration median (range)
32% (58/181)
 7 days (1–132)
Venetoclax Discontinuation Rate 40% (119/297)
Venetoclax Discontinued for AE 7.7% (23/297)